The domestic poultry vaccine market, with annual sales exceeding RM200 million, presents a promising opportunity for growth.
“This anticipated growth is driven by the expansion of the poultry industry, which is continuously evolving to meet the increasing global appetite for poultry products. As poultry farming scales up, the need for effective vaccines to safeguard flocks against diseases will become even more pronounced, fuelling a surge in vaccine demand.
“We are poised to capitalise on this lucrative market with our latest product, Poulvac Procerta HVT ND. This demonstrates the vaccine’s strong effectiveness in protecting flocks from a highly virulent strain of Newcastle Disease Virus , he added. With NDV posing a significant threat to poultry health, the Poulvac Procerta HVT ND offers the industry a highly effective option for controlling and preventing this serious disease with its proven protection and advanced technology.
Innovations such as recombinant HVT and sub-unit vaccines offer high efficacy across various poultry species, including broilers, layer chickens and breeders.In addition to advancing vaccine technology, Lim said, improvements in vaccine delivery systems are also crucial.